[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 13, 1981

Neomycin Sensitivity and the MMR Vaccine

Author Affiliations

Emory School of Medicine
Center for Disease Control Atlanta

JAMA. 1981;245(6):571. doi:10.1001/jama.1981.03310310017008
Abstract

To the Editor.—  Hypersensitivity to a medication is customarily considered a contraindication to its use. In the case of measles, mumps, and rubella (MMR) vaccine that contains neomycin, the package insert lists hypersensitivity to neomycin as a contraindication to the use of this preparation. Allergy to neomycin is commonly manifested as contact dermatitis and can be proved by patch testing with 20% neomycin in petrolatum or by intradermal testing at a concentration of 1:100.1 When the concentration for intradermal testing is decreased to 1:1,000, some persons will have a

×